Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542848 | 0.94 | CYP3A4 (0.76) | CYP3A4CRBNTRPV1BRD4KIF11 | |
| SCHEMBL2130293 | 0.94 | CYP3A4 (0.76) | CYP3A4CRBNTRPV1BRD4KIF11 | |
| SCHEMBL1764637 | 0.89 | CYP3A4 (0.53) | CYP3A4CRBNBRD4 | |
| SCHEMBL1764546 | 0.87 | CYP3A4 (0.88) | CYP3A4CRBNTRPV1PADI4 | |
| SCHEMBL1764958 | 0.87 | CYP3A4 (0.66) | CYP3A4CRBNTRPV1BRD4PADI4 | |
| SCHEMBL1542924 | 0.85 | CYP3A4 (0.76) | CYP3A4CRBNTRPV1PADI4 | |
| SCHEMBL2127562 | 0.85 | CYP3A4 (0.76) | CYP3A4CRBNTRPV1PADI4 | |
| SCHEMBL1542609 | 0.84 | CYP3A4 (0.75) | CYP3A4CRBNTRPV1KIF11PADI4 | |
| SCHEMBL1542606 | 0.84 | CYP3A4 (0.75) | CYP3A4CRBNTRPV1KIF11PADI4 | |
| SCHEMBL1764712 | 0.84 | CYP3A4 (0.66) | CYP3A4CRBNTRPV1BRD4PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | claimed |
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2501679-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061243-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HCCS, EIF2AK2, RNASE1 | CYP3A4 60/4885CRBN 3075/4885TRPV1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.